Lynch Regenerative Medicine, a pioneering company in the field of skin rejuvenation and regeneration, has successfully completed its Series A financing round. This significant milestone marks a new chapter in the company's mission to bring innovative skincare solutions to the global market. The financing was spearheaded by Champion VC, a family office investor managing assets for the Frist family of Nashville, Tennessee, alongside Dr. Samuel Lynch, the founder and CEO of LRM.
At the heart of LRM's groundbreaking approach is the use of pure platelet-derived growth factor (PDGF), a tissue growth factor that has received FDA approval and recognition from international regulatory bodies for its safety and efficacy in human tissue regeneration and wound healing. This patented PDGF-based technology has already proven its worth as the main active component in four FDA-approved products, including solutions for orthopedic tissue healing, periodontal tissue regeneration, and skin regeneration. Over the past 15 years, these products have positively impacted millions of patients worldwide, setting a strong foundation for LRM's venture into the skincare aesthetics market.
Dr. Samuel Lynch, a renowned figure in the regenerative medicine field, brings a wealth of experience to this venture. LRM represents his third company to introduce pure PDGF-based products to the market, underlining his expertise and track record in this specialized area. The skincare market, being the largest and fastest-growing segment for this technology, presents an exciting opportunity for LRM to address the increasing demand for safe, effective, and scientifically proven solutions for skin rejuvenation and regeneration.
LRM has already made its mark in the skincare industry with the launch of Ariessence™ Pure PDGF+, its first product aimed at improving skin aesthetics. Available in leading med/spa clinics and aesthetic-focused practices, including dermatology and plastic surgery offices, Ariessence Pure PDGF+ is designed for topical use to enhance aesthetic outcomes associated with various procedures such as micro-needling, dermabrasion, laser treatments, and plastic surgery. The product leverages the regenerative properties of PDGF to accelerate and improve the appearance of healthier-looking skin post-procedure.
The successful closure of the Series A financing round positions LRM for significant growth and expansion. The company plans to utilize the capital to fuel its commercialization strategy, focusing on expanding its team by bringing in top-tier talent across various disciplines. This includes strengthening its capabilities in commercialization, business development, clinical development, and regulatory affairs. Such strategic expansion is crucial for LRM to capitalize on the vast potential of the $100 billion aesthetics and wound-care markets.
In the transaction, PH Partners acted as financial advisors to LRM, while Bass, Berry & Sims provided legal counsel. This professional support underscores the significance of the financing round and the potential impact of LRM's innovations in the skincare industry. The involvement of these reputable firms adds credibility to LRM's vision and business model.
Looking ahead, LRM is poised to redefine the future of aesthetic regenerative medicine. By leveraging its regenerative medicine heritage and long-standing commitment to developing safe and effective regenerative products of the highest quality, the company aims to deliver exceptional results for both its customers and their patients. Founded in 2023 and based in Franklin, Tennessee, LRM stands at the forefront of a new era in skincare, where science-backed solutions meet the growing demand for effective skin rejuvenation and regeneration treatments.
